- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
- Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
- BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
- BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
- BeiGene to Present at Upcoming Investor Conferences
- BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
- BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
More ▼
Key statistics
On Thursday, Beigene Ltd (BGNE:NSQ) closed at 156.39, 17.63% above the 52 week low of 132.95 set on Feb 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 157.00 |
---|---|
High | 157.38 |
Low | 155.09 |
Bid | 151.00 |
Offer | 160.00 |
Previous close | 155.08 |
Average volume | 189.16k |
---|---|
Shares outstanding | 104.43m |
Free float | 102.72m |
P/E (TTM) | -- |
Market cap | 17.18bn USD |
EPS (TTM) | -8.50 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼